Nanodroplets engineered with folate carbon dots for enhanced cancer cell uptake toward theranostic application

Show simple item record

dc.contributor.author Kumawat, Akshant
dc.contributor.author Saini, Bhawna
dc.contributor.author Ghoroi, Chinmay
dc.coverage.spatial United States of America
dc.date.accessioned 2024-08-02T14:02:37Z
dc.date.available 2024-08-02T14:02:37Z
dc.date.issued 2024-07
dc.identifier.citation Kumawat, Akshant; Saini, Bhawna and Ghoroi, Chinmay, "Nanodroplets engineered with folate carbon dots for enhanced cancer cell uptake toward theranostic application", ACS Applied Bio Materials, DOI: 10.1021/acsabm.4c00633, Jul. 2024.
dc.identifier.issn 2576-6422
dc.identifier.uri https://doi.org/10.1021/acsabm.4c00633
dc.identifier.uri https://repository.iitgn.ac.in/handle/123456789/10281
dc.description.abstract The research in nanotherapeutics is rapidly advancing, particularly in the realm of nanoconstructs for drug delivery. This study introduces folate-based carbon dot-decorated nanodroplets (f-Dnm), synthesized from a binary mixture of negatively charged folic acid carbon dots (f-CDs) and cationic-branched polyethylenimine (PEI). The uniformly spherical nanodroplets with an average diameter of 115 ± 15 nm exhibit notable photoluminescence. Surface potential analysis reveals a significant change upon coacervation, attributed to strong electrostatic interactions between f-CD and PEI. The engineered nanodroplets show excellent colloidal and photostability even after 6 months of storage at room temperature. The pH-dependent self-assembly and disassembly properties of f-Dnm are explored for drug loading and release studies using doxorubicin (DOX) as a model anticancer drug. Moreover, the f-Dnm nanocarrier demonstrates significantly higher drug loading capabilities (∼90%). In vitro release studies of doxorubicin-loaded f-Dnm [f-Dnm(DOX)] reveal 5 times higher drug release at lysosomal pH 5.4 compared to that at physiological blood pH 7.4. Cytocompatibility assessments using the MTT assay on HeLa, A549, and NIH-3T3 cells confirm the nontoxic nature of f-Dnm, even at high concentrations. Additionally, f-Dnm(DOX) exhibits higher cytotoxicity in HeLa cells compared to f-CD(DOX) at similar DOX concentrations. Cellular uptake studies show an increased uptake of f-Dnm in folate receptor-positive HeLa and MDA-MB 231 cells. Hemolysis assay validated the biocompatibility of the developed formulation. Overall, these engineered nanodroplets represent a class of nontoxic nanocarriers that offer promising potential as nanotherapeutics for folate receptor-positive cells.
dc.description.statementofresponsibility by Akshant Kumawat, Bhawna Saini and Chinmay Ghoroi
dc.language.iso en_US
dc.publisher American Chemical Society
dc.subject Folate carbon dot
dc.subject Nanodroplet
dc.subject Drug delivery
dc.subject Nanocarrier
dc.subject Theranostic
dc.subject Cancer
dc.title Nanodroplets engineered with folate carbon dots for enhanced cancer cell uptake toward theranostic application
dc.type Article
dc.relation.journal ACS Applied Bio Materials


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account